berberine has been researched along with Diabetes Mellitus in 38 studies
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To give an overview of the therapeutic potential of berberine as a treatment for dementia associated with diabetes." | 9.05 | Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review. ( Bell, J; Bligh, A; Katsuno, T; Parkinson, J; Shinjyo, N, 2020) |
| "Berberine is an alkaloid found in plants." | 6.72 | Berberine in the Treatment of Diabetes Mellitus: A Review. ( Baska, A; Gałązka, P; Leis, K, 2021) |
| "Berberine treatment also alleviated DN-induced changes in the expression of proteins involved in iron transport or iron uptake." | 5.91 | Treatment of berberine alleviates diabetic nephropathy by reducing iron overload and inhibiting oxidative stress. ( Cai, F; Chen, J; Li, C; Wang, Y; Yue, S; Zhong, Y; Zhu, W, 2023) |
| "Diabetic atherosclerosis is characterized by hyperglycemia, hyperinsulinemia, and dyslipidemia." | 5.72 | Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARα in ApoE ( Hu, C; Ma, C; Man, B; Xiang, J; Yang, G; Yang, S, 2022) |
| "A double-blind, randomized, placebo-controlled, dose ranging study was carried out that compared three doses of berberine ursodeoxycholate (BUDCA) to placebo in a cohort of subjects with a history of hypercholesterolemia and serum LDL cholesterol levels above 2." | 5.34 | Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. ( Bai, R; Di Bisceglie, AM; Lavin, P; Liu, L; Watts, GF; Yu, M, 2020) |
| " Lycopene and berberine are natural plants with a wide range of beneficial effects including protective activities against metabolic disorders such as diabetes and cardiovascular diseases." | 5.12 | Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review. ( Hedayati, N; Naeini, MB; Oskouei, Z; Tabeshpour, J, 2021) |
| "To give an overview of the therapeutic potential of berberine as a treatment for dementia associated with diabetes." | 5.05 | Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review. ( Bell, J; Bligh, A; Katsuno, T; Parkinson, J; Shinjyo, N, 2020) |
| "Our findings suggest an additional mechanism of the hypoglycemic activity of berberine by demonstrating its ability to acutely inhibit the α-glucosidase, and support the traditional use of berberine and Chinese Goldthread Rhizome for the treatment of diabetes mellitus." | 3.78 | Berberine acutely inhibits the digestion of maltose in the intestine. ( Li, ZQ; Qi, H; Qie, XD; Wu, YL; Zhao, MQ; Zuo, DY, 2012) |
| "However, to assess the anti-diabetic nephropathy effects and safety of berberine in a more accurate manner, additional large-scale, long-term, and high-quality preclinical trials are needed to confirm these findings before clinical application." | 2.82 | Protective effect of berberine in diabetic nephropathy: A systematic review and meta-analysis revealing the mechanism of action. ( Hu, S; Li, W; Liu, E; Ma, X; Wang, J; Wei, P; Xiang, J; Zeng, J; Zhang, X; Zhang, Y, 2022) |
| "Berberine is an alkaloid found in plants." | 2.72 | Berberine in the Treatment of Diabetes Mellitus: A Review. ( Baska, A; Gałązka, P; Leis, K, 2021) |
| " However, the pharmacological study found that the bioavailability of berberine is extremely low." | 2.53 | [Research progress of relationship between diabetes and intestinal epithelial tight junction barrier and intervetion of berberine]. ( Dong, H; Lu, FE; Qin, X, 2016) |
| " It is necessary to improve the oral bioavailability of BBR before it can be used in many clinical applications." | 2.53 | Research progress on berberine with a special focus on its oral bioavailability. ( Liu, CS; Long, XY; Zhang, YF; Zheng, YR, 2016) |
| "Berberine (BBR) is an isoquinoline plant alkaloid endowed with several pharmacological activities, including anti-microbial, glucose- and cholesterol-lowering, anti-tumoral and immunomodulatory properties." | 2.52 | Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. ( Catapano, AL; Pirillo, A, 2015) |
| "Berberine is an isoquinoline alkaloid isolated from Chinese herbs such as Coptidis Rhizome." | 2.47 | Advances in structural modifications and biological activities of berberine: an active compound in traditional Chinese medicine. ( Chen, WM; Huang, ZJ; Lan, P; Sun, PH; Zeng, Y, 2011) |
| "Berberine is a isoquinoline alkaloid extracted from Chinese herbs such as Coptidis rhizome." | 2.44 | [Advances in the study of berberine and its derivatives]. ( Chen, KX; Li, B; Zhu, WL, 2008) |
| "Berberine treatment also alleviated DN-induced changes in the expression of proteins involved in iron transport or iron uptake." | 1.91 | Treatment of berberine alleviates diabetic nephropathy by reducing iron overload and inhibiting oxidative stress. ( Cai, F; Chen, J; Li, C; Wang, Y; Yue, S; Zhong, Y; Zhu, W, 2023) |
| "Berberine (BBR) is a natural compound extracted from a Chinese herb, with a clinically reported anti‑DCM effect; however, its molecular mechanisms have not yet been fully elucidated." | 1.91 | Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR‑18a‑3p/Gsdmd pathway. ( Cai, SQ; Chen, DF; Cheng, CF; Fang, HC; Huang, XJ; Li, ZF; Liu, HL; Ren, ZX; Xiong, Y; Yang, L; Ye, SY; Zhao, LJ, 2023) |
| "Diabetic atherosclerosis is characterized by hyperglycemia, hyperinsulinemia, and dyslipidemia." | 1.72 | Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARα in ApoE ( Hu, C; Ma, C; Man, B; Xiang, J; Yang, G; Yang, S, 2022) |
| "KRas is frequently mutated in pancreatic cancers." | 1.62 | GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021) |
| "Berberine is a plant alkaloid, used in Chinese herbal medicine." | 1.56 | Berberine protects against diabetic kidney disease via promoting PGC-1α-regulated mitochondrial energy homeostasis. ( Dong, H; Fang, K; Gong, J; Jiang, M; Lu, F; Qin, X; Su, H; Yu, X; Yuan, F; Yuan, X; Zhao, Y, 2020) |
| "Considering the potential oral administration sequences and role of microbiota for metformin (MET) and berberine (BBR) during anti-diabetic treatments, the current study aimed to investigate the pharmacokinetic interactions between MET and BBR in rats after oral administration at different sequences and impacts of microbiota on such interactions." | 1.51 | Pharmacokinetic interactions between metformin and berberine in rats: Role of oral administration sequences and microbiota. ( Chan, PKS; Cheung, SCK; Kong, APS; Lin, L; Lyu, Y; Shaw, PC; Yang, M; Yang, X; Zhang, Y; Zuo, Z, 2019) |
| "Berberine was found to inhibit platelet aggregation, superoxide production via modulating AR, NOX, and glutathione reductase activities in high glucose (HG) treated platelets." | 1.51 | Berberine mitigates high glucose-potentiated platelet aggregation and apoptosis by modulating aldose reductase and NADPH oxidase activity. ( Girish, KS; Hemshekhar, M; Kemparaju, K; Paul, M, 2019) |
| "Berberine is an isoquinoline alkaloid present in several plant species, including Coptis sp." | 1.40 | Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications. ( Chen, C; Fichna, J; Li, Y; Storr, M; Yu, Z, 2014) |
| "Cellular efflux transporters, especially P-glycoprotein (P-gp), impel berberine (BBR) out of cells, and therefore reduce bioavailability of the compound." | 1.39 | Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux. ( Jiang, JD; Kong, WJ; Pang, J; Ren, G; Shan, YQ; Si, SY; Song, DQ; Wang, YX; Yao, J; You, XF; Zhao, ZY, 2013) |
| "Berberine (BBR) was previously found to have beneficial effects on renal injury in experimental diabetic rats." | 1.36 | Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway. ( Huang, H; Jiang, Q; Lan, T; Li, W; Liu, P; Liu, W; Shen, X; Xie, X; Xu, S, 2010) |
| " Our previous work demonstrated that dihydroberberine (dhBBR) has enhanced bioavailability and in vivo efficacy compared with berberine." | 1.36 | 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. ( Chen, AF; Cheng, Z; Gu, M; Hu, LH; Li, J; Li, JY; Li, YY; Sheng, L; Wu, F; Zhang, HK; Zhang, LN, 2010) |
| "Berberine treatment resulted in increased AMP-activated protein kinase (AMPK) activity in 3T3-L1 adipocytes and L6 myotubes, increased GLUT4 translocation in L6 cells in a phosphatidylinositol 3' kinase-independent manner, and reduced lipid accumulation in 3T3-L1 adipocytes." | 1.33 | Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. ( Cho, HJ; Gosby, A; Hohnen-Behrens, C; James, DE; Kim, CT; Kim, JB; Kim, KH; Kim, WS; Kraegen, EW; Lee, CH; Lee, YS; Oh, WK; Shen, Y; Ye, JM; Yoon, MJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (10.53) | 29.6817 |
| 2010's | 21 (55.26) | 24.3611 |
| 2020's | 13 (34.21) | 2.80 |
| Authors | Studies |
|---|---|
| Qiu, S | 1 |
| Yang, WZ | 1 |
| Yao, CL | 1 |
| Shi, XJ | 1 |
| Li, JY | 2 |
| Lou, Y | 1 |
| Duan, YN | 1 |
| Wu, WY | 1 |
| Guo, DA | 1 |
| Hedayati, N | 1 |
| Oskouei, Z | 1 |
| Tabeshpour, J | 1 |
| Naeini, MB | 1 |
| Ni, WJ | 1 |
| Guan, XM | 1 |
| Zeng, J | 2 |
| Zhou, H | 1 |
| Meng, XM | 1 |
| Tang, LQ | 1 |
| Maity, B | 1 |
| Alam, S | 1 |
| Samanta, S | 1 |
| Prakash, RG | 1 |
| Govindaraju, T | 1 |
| Man, B | 1 |
| Hu, C | 1 |
| Yang, G | 1 |
| Xiang, J | 2 |
| Yang, S | 1 |
| Ma, C | 1 |
| Urasaki, Y | 1 |
| Le, TT | 1 |
| Hu, S | 1 |
| Wang, J | 1 |
| Liu, E | 1 |
| Zhang, X | 1 |
| Li, W | 2 |
| Wei, P | 1 |
| Zhang, Y | 2 |
| Ma, X | 1 |
| Wang, Y | 1 |
| Yue, S | 1 |
| Cai, F | 1 |
| Zhu, W | 1 |
| Zhong, Y | 1 |
| Chen, J | 1 |
| Li, C | 1 |
| Yang, L | 1 |
| Cheng, CF | 1 |
| Li, ZF | 1 |
| Huang, XJ | 1 |
| Cai, SQ | 1 |
| Ye, SY | 1 |
| Zhao, LJ | 1 |
| Xiong, Y | 1 |
| Chen, DF | 1 |
| Liu, HL | 1 |
| Ren, ZX | 1 |
| Fang, HC | 1 |
| Lyu, Y | 1 |
| Yang, M | 1 |
| Lin, L | 1 |
| Yang, X | 1 |
| Cheung, SCK | 1 |
| Shaw, PC | 1 |
| Chan, PKS | 1 |
| Kong, APS | 1 |
| Zuo, Z | 1 |
| Qin, X | 2 |
| Jiang, M | 1 |
| Zhao, Y | 1 |
| Gong, J | 1 |
| Su, H | 1 |
| Yuan, F | 1 |
| Fang, K | 1 |
| Yuan, X | 1 |
| Yu, X | 1 |
| Dong, H | 2 |
| Lu, F | 1 |
| Shinjyo, N | 1 |
| Parkinson, J | 1 |
| Bell, J | 1 |
| Katsuno, T | 1 |
| Bligh, A | 1 |
| Baska, A | 1 |
| Leis, K | 1 |
| Gałązka, P | 1 |
| Di Bisceglie, AM | 1 |
| Watts, GF | 1 |
| Lavin, P | 1 |
| Yu, M | 1 |
| Bai, R | 1 |
| Liu, L | 2 |
| Abrams, SL | 1 |
| Akula, SM | 1 |
| Meher, AK | 1 |
| Steelman, LS | 1 |
| Gizak, A | 1 |
| Duda, P | 1 |
| Rakus, D | 1 |
| Martelli, AM | 1 |
| Ratti, S | 1 |
| Cocco, L | 1 |
| Montalto, G | 1 |
| Cervello, M | 1 |
| Ruvolo, P | 1 |
| Libra, M | 1 |
| Falzone, L | 1 |
| Candido, S | 1 |
| McCubrey, JA | 1 |
| Lu, FE | 1 |
| Di Pierro, F | 1 |
| Putignano, P | 1 |
| Villanova, N | 1 |
| Paul, M | 1 |
| Hemshekhar, M | 1 |
| Kemparaju, K | 1 |
| Girish, KS | 1 |
| Yue, SJ | 1 |
| Liu, J | 1 |
| Wang, AT | 1 |
| Meng, XT | 1 |
| Yang, ZR | 1 |
| Peng, C | 1 |
| Guan, HS | 1 |
| Wang, CY | 1 |
| Yan, D | 1 |
| Shan, YQ | 2 |
| Zhu, YP | 1 |
| Pang, J | 2 |
| Wang, YX | 2 |
| Song, DQ | 2 |
| Kong, WJ | 2 |
| Jiang, JD | 2 |
| Abd El-Wahab, AE | 1 |
| Ghareeb, DA | 1 |
| Sarhan, EE | 1 |
| Abu-Serie, MM | 1 |
| El Demellawy, MA | 1 |
| Chen, C | 1 |
| Yu, Z | 1 |
| Li, Y | 1 |
| Fichna, J | 1 |
| Storr, M | 1 |
| Pirillo, A | 1 |
| Catapano, AL | 1 |
| Liu, CS | 1 |
| Zheng, YR | 1 |
| Zhang, YF | 1 |
| Long, XY | 1 |
| Wu, YS | 1 |
| Chen, YT | 1 |
| Bao, YT | 1 |
| Li, ZM | 1 |
| Zhou, XJ | 1 |
| He, JN | 1 |
| Dai, SJ | 1 |
| Li, CY | 1 |
| Chang, W | 1 |
| Yin, J | 1 |
| Zhang, H | 1 |
| Ye, J | 1 |
| Li, B | 1 |
| Zhu, WL | 1 |
| Chen, KX | 1 |
| Lu, SS | 1 |
| Yu, YL | 1 |
| Zhu, HJ | 1 |
| Liu, XD | 1 |
| Liu, YW | 1 |
| Wang, P | 1 |
| Xie, L | 1 |
| Wang, GJ | 1 |
| Lan, T | 1 |
| Shen, X | 1 |
| Liu, P | 1 |
| Liu, W | 1 |
| Xu, S | 1 |
| Xie, X | 1 |
| Jiang, Q | 1 |
| Huang, H | 1 |
| Cheng, Z | 1 |
| Chen, AF | 1 |
| Wu, F | 1 |
| Sheng, L | 1 |
| Zhang, HK | 1 |
| Gu, M | 1 |
| Li, YY | 1 |
| Zhang, LN | 1 |
| Hu, LH | 1 |
| Li, J | 1 |
| Shen, N | 1 |
| Li, CN | 1 |
| Huan, Y | 1 |
| Shen, ZF | 1 |
| Chatuphonprasert, W | 1 |
| Nemoto, N | 1 |
| Sakuma, T | 1 |
| Jarukamjorn, K | 1 |
| Huang, ZJ | 1 |
| Zeng, Y | 1 |
| Lan, P | 1 |
| Sun, PH | 1 |
| Chen, WM | 1 |
| Zhao, HL | 1 |
| Sui, Y | 1 |
| Qiao, CF | 1 |
| Yip, KY | 1 |
| Leung, RK | 1 |
| Tsui, SK | 1 |
| Lee, HM | 1 |
| Wong, HK | 1 |
| Zhu, X | 1 |
| Siu, JJ | 1 |
| He, L | 1 |
| Guan, J | 1 |
| Liu, LZ | 1 |
| Xu, HX | 1 |
| Tong, PC | 1 |
| Chan, JC | 1 |
| Li, ZQ | 1 |
| Zuo, DY | 1 |
| Qie, XD | 1 |
| Qi, H | 1 |
| Zhao, MQ | 1 |
| Wu, YL | 1 |
| Ren, G | 1 |
| Zhao, ZY | 1 |
| Yao, J | 1 |
| You, XF | 1 |
| Si, SY | 1 |
| Lee, YS | 1 |
| Kim, WS | 1 |
| Kim, KH | 1 |
| Yoon, MJ | 1 |
| Cho, HJ | 1 |
| Shen, Y | 1 |
| Ye, JM | 1 |
| Lee, CH | 1 |
| Oh, WK | 1 |
| Kim, CT | 1 |
| Hohnen-Behrens, C | 1 |
| Gosby, A | 1 |
| Kraegen, EW | 1 |
| James, DE | 1 |
| Kim, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With Hypercholesterolemia[NCT03381287] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2018-04-13 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| To Test the Efficacy of Novel Berberine Emulsification by TPGS or Quillaja Extract on the Absorption of Berberine Compared to Berberine Powder in Humans[NCT03438292] | 32 participants (Actual) | Interventional | 2018-09-25 | Completed | |||
| A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders[NCT02983188] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2018-04-25 | Completed | ||
| A Phase I, Randomized, Crossover, Double-blind, Pharmacokinetic Study of Berberine Released From Cyclodextrin in Healthy Volunteers[NCT04918667] | Phase 1 | 16 participants (Anticipated) | Interventional | 2024-09-30 | Not yet recruiting | ||
| The Therapeutic Effects of Combination of Insulin With Berberine on the Patients With Stess Hyperlipemia:a Prospective, Double Blind, Randomized, Placebo-controlled, Single-center Clinical Trial[NCT02806999] | Phase 4 | 200 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 28
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg BID | 1.770 | 3370 |
| HTD1801 250 mg BID | 0.676 | 962 |
| HTD1801 500 mg BID | 1.510 | 1900 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 1
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg | 0.865 | 2900 |
| HTD1801 250 mg | 0.390 | 923 |
| HTD1801 500 mg | 0.441 | 1900 |
TEAEs are defined as any AEs that commenced on or after exposure to study drug or any pre-existing AE that worsened in either intensity or frequency after exposure to study drug. (NCT03381287)
Timeframe: 4 weeks
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| TEAE | Serious TEAE | Severe TEAE | Drug-related TEAEs | TEAEs leading to treatment interrupted or discontinued | |
| HTD1801 1000 mg BID | 11 | 1 | 0 | 6 | 1 |
| HTD1801 250 mg BID | 10 | 0 | 0 | 2 | 0 |
| HTD1801 500 mg BID | 8 | 0 | 0 | 7 | 0 |
| Placebo | 8 | 0 | 1 | 4 | 0 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -32.192 | -34.382 |
| HTD1801 250 mg BID | -38.672 | -46.458 |
| HTD1801 500 mg BID | -41.295 | 47.246 |
| Placebo | -41.743 | -33.153 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -13.034 | -21.916 |
| HTD1801 250 mg BID | -19.527 | -11.239 |
| HTD1801 500 mg BID | 222.4113 | 242.570 |
| Placebo | -4.975 | 10.582 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -9.296 | -9.767 |
| HTD1801 250 mg BID | -3.390 | -7.674 |
| HTD1801 500 mg BID | -1.1550 | 0.372 |
| Placebo | 3.624 | -3.585 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -2.240 | 6.256 |
| HTD1801 250 mg BID | -5.788 | 7.684 |
| HTD1801 500 mg BID | 12.798 | 25.882 |
| Placebo | 1.724 | 36.778 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 28
| Intervention | hours (Mean) |
|---|---|
| Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg BID | 7.53 |
| HTD1801 500 mg BID | 7.60 |
(NCT03381287)
Timeframe: 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 1
| Intervention | hours (Mean) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg | 7.79 | 5.24 |
| HTD1801 250 mg | 9.04 | 2.79 |
| HTD1801 500 mg | 10.60 | 8.43 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 28
| Intervention | hours (Median) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg BID | 4.0 | 3.0 |
| HTD1801 250 mg BID | 4.0 | 3.0 |
| HTD1801 500 mg BID | 4.0 | 4.0 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 1
| Intervention | hours (Median) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg | 4.0 | 4.0 |
| HTD1801 250 mg | 3.5 | 2.0 |
| HTD1801 500 mg | 4.0 | 3.0 |
12 reviews available for berberine and Diabetes Mellitus
| Article | Year |
|---|---|
Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review.
Topics: Berberine; Biological Availability; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mel | 2021 |
Protective effect of berberine in diabetic nephropathy: A systematic review and meta-analysis revealing the mechanism of action.
Topics: Animals; Berberine; Cholesterol, LDL; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Triglyc | 2022 |
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Berberine; Brain; Cholinergic Agonists; Cognitive Dysfunct | 2020 |
Berberine in the Treatment of Diabetes Mellitus: A Review.
Topics: Animals; Berberine; Diabetes Mellitus; Glucose; Humans; Insulin; Insulin Resistance; Insulin-Secreti | 2021 |
[Research progress of relationship between diabetes and intestinal epithelial tight junction barrier and intervetion of berberine].
Topics: Berberine; Diabetes Mellitus; Humans; Intestinal Mucosa; Permeability; Tight Junctions | 2016 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Research progress on berberine with a special focus on its oral bioavailability.
Topics: Administration, Oral; Animals; Berberine; Biological Availability; Diabetes Mellitus; Humans; Hyperl | 2016 |
Non-coding RNAs and Berberine: A new mechanism of its anti-diabetic activities.
Topics: Animals; Berberine; Diabetes Mellitus; Diet, High-Fat; Humans; Hypoglycemic Agents; RNA, Untranslate | 2017 |
Traditional chinese medicine in treatment of metabolic syndrome.
Topics: Animals; Berberine; Diabetes Mellitus; Glucose; Humans; Hypoglycemic Agents; Hypolipidemic Agents; L | 2008 |
[Advances in the study of berberine and its derivatives].
Topics: Alzheimer Disease; Animals; Anti-Arrhythmia Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Be | 2008 |
[Advances of the mechanism study on berberine in the control of blood glucose and lipid as well as metabolism disorders].
Topics: AMP-Activated Protein Kinase Kinases; Animals; Berberine; Blood Glucose; Coptis; Diabetes Mellitus; | 2010 |
Advances in structural modifications and biological activities of berberine: an active compound in traditional Chinese medicine.
Topics: Alzheimer Disease; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antimalarials; Antineop | 2011 |
1 trial available for berberine and Diabetes Mellitus
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia.
Topics: Adult; Aged; Berberine; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; D | 2020 |
25 other studies available for berberine and Diabetes Mellitus
| Article | Year |
|---|---|
Malonylginsenosides with Potential Antidiabetic Activities from the Flower Buds of Panax ginseng.
Topics: Animals; Chromatography, Liquid; Diabetes Mellitus; Drugs, Chinese Herbal; Flowers; Ginsenosides; Hy | 2017 |
Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/GLUT1 signalling pathway.
Topics: Animals; Berberine; Cell Cycle; Cell Division; Cell Proliferation; Diabetes Mellitus; Diabetic Nephr | 2022 |
Antioxidant Silk Fibroin Composite Hydrogel for Rapid Healing of Diabetic Wound.
Topics: Animals; Antioxidants; Berberine; Diabetes Mellitus; Fibroins; Hydrogels; Melanins; Rats; Rats, Wist | 2022 |
Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARα in ApoE
Topics: Animals; Apolipoproteins E; Atherosclerosis; Berberine; Diabetes Mellitus; Glucose; Inflammation; Kr | 2022 |
A Composition of Phytonutrients for Glycemic and Weight Management.
Topics: Acrolein; Animals; Berberine; Blood Glucose; Curcumin; Diabetes Mellitus; Disease Models, Animal; Fa | 2022 |
Treatment of berberine alleviates diabetic nephropathy by reducing iron overload and inhibiting oxidative stress.
Topics: Animals; Berberine; Diabetes Mellitus; Diabetic Nephropathies; Iron; Iron Overload; Kidney; Oxidativ | 2023 |
Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR‑18a‑3p/Gsdmd pathway.
Topics: Animals; Berberine; Diabetes Mellitus; Diabetic Cardiomyopathies; Inflammasomes; MicroRNAs; Pyroptos | 2023 |
Pharmacokinetic interactions between metformin and berberine in rats: Role of oral administration sequences and microbiota.
Topics: Administration, Oral; Animals; Bacteria; Berberine; Diabetes Mellitus; Drug Administration Schedule; | 2019 |
Berberine protects against diabetic kidney disease via promoting PGC-1α-regulated mitochondrial energy homeostasis.
Topics: Animals; Berberine; Diabetes Mellitus; Diabetic Nephropathies; Homeostasis; Humans; Mice; Mitochondr | 2020 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound | 2021 |
Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in diabetic patients with dyslipidemia.
Topics: Aged; Berberine; Biological Products; Diabetes Mellitus; Dietary Supplements; Dyslipidemias; Female; | 2018 |
Berberine mitigates high glucose-potentiated platelet aggregation and apoptosis by modulating aldose reductase and NADPH oxidase activity.
Topics: Aldehyde Reductase; Antioxidants; Apoptosis; Arterial Occlusive Diseases; Berberine; Blood Platelets | 2019 |
Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids.
Topics: 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; | 2019 |
Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function.
Topics: Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinoli | 2013 |
In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects.
Topics: Acetylcholinesterase; alpha-Glucosidases; Animals; Antineoplastic Agents; Antioxidants; Berberine; B | 2013 |
Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications.
Topics: Animals; Anti-Inflammatory Agents; Antidiarrheals; Antineoplastic Agents; Berberine; Berberis; Cardi | 2014 |
Identification and Verification of Potential Therapeutic Target Genes in Berberine-Treated Zucker Diabetic Fatty Rats through Bioinformatics Analysis.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Berberine; Blood Glucose; Carbohydrate M | 2016 |
Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats.
Topics: Animals; Antibiotics, Antineoplastic; Berberine; Diabetes Mellitus; Disease Models, Animal; Gene Exp | 2009 |
Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway.
Topics: Albuminuria; Animals; Berberine; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Nephro | 2010 |
8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models.
Topics: Animals; Berberine; Diabetes Mellitus; Electron Transport; Glucose; Humans; Hypoglycemic Agents; Mal | 2010 |
Modulations of cytochrome P450 expression in diabetic mice by berberine.
Topics: Animals; Berberine; Blood Glucose; Cytochrome P-450 Enzyme System; Diabetes Mellitus; Gene Expressio | 2012 |
Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression.
Topics: Animals; Berberine; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus; Drugs, C | 2012 |
Berberine acutely inhibits the digestion of maltose in the intestine.
Topics: Animals; Berberine; Blood Glucose; Caco-2 Cells; Colon; Coptis; Diabetes Mellitus; Digestion; Dogs; | 2012 |
Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Berberine; Biological Availability | 2013 |
Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Berberine; Cell Li | 2006 |